Particle.news

Hospitals Sue CVS Over Alleged $250M 340B Repricing Scheme

The lawsuits say CVS affiliates systematically rerouted discounts meant for safety-net hospitals into corporate profit, a claim that could prompt tighter oversight of contract pharmacy practices.

Overview

  • Three health systems, which filed federal complaints Thursday, May 21, 2026, say CVS Health and its affiliates improperly diverted about $250 million in savings from the federal 340B drug discount program.
  • The lawsuits describe a timing- and adjudication-based method where specialty drug claims were first paid at standard network rates and later re-priced by CVS entities so the companies kept the difference.
  • Plaintiffs quantify losses by hospital: Mount Sinai alleges more than $121 million, Michigan Medicine and Sparrow claim over $66 million, and the University of Kansas Hospital Authority cites nearly $62 million.
  • The complaints say hospitals were denied audits and that some contract pharmacy arrangements were cut or ended after concerns were raised; the cases seek repayment, records, damages and court orders to stop the practices.
  • The suits arrive against a backdrop of prior enforcement actions involving CVS pharmacy units and could spur policy or regulatory scrutiny of how 340B eligibility and contract pharmacies are handled, with direct effects on programs that fund care for uninsured and low-income patients.